Scottsdale, Arizona 5/17/2008 10:01:27 AM
News / Finance

QualityStocks.net News – Kensey Nash Corp. (KNSY) Enters Into Sales Agreement with Spectranetics

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

 

We would like to highlight Kensey Nash Corp. (NASDAQ: KNSY). The company is a medical device company known for product development and technology in the fields of resorbable biomaterials and endovascular devices, used in a variety of medical procedures. The Company provides a range of products in multiple medical markets, primarily the endovascular and orthopaedic markets. The Company also invents and develops the Angio-Seal Vascular Closure Device, which is exclusively licensed to St. Jude Medical, Inc.

 

In the Company’s recent news,

 

Kensey Nash Corp. (KNSY) entered into a definitive agreement with Spectranetics Corporation. Under the agreement, the company will sell its endovascular business, including the ThromCat™, QuickCat™ and Safecross™ products, to Spectranetics. Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in multiple, minimally invasive cardiovascular procedures.

 

Kensey Nash will receive up to $24M consisting of a $10M initial cash payment, $8.0M in future product development milestone payments, and a $6.0M milestone associated with cumulative sales. Additionally, the company will receive royalties on future sales of the ThromCat™ and SafeCross™ products upon the transfer of product manufacturing to Spectranetics. There will be no royalty payments related to future sales of the QuickCat product.

 

The agreement specifies that Kensey Nash will manufacture the ThromCat and SafeCross products for Spectranetics for an initial three-year period. The QuickCat product will be manufactured by the company for a six month minimum. Worldwide sales and marketing of all endovascular products will be the responsibility of Spectranetics. The transaction is expected to close by June 30, 2008.

 

About QualityStocks

 

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

 

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

 

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.